It proves its anti-tumor effect by inhibiting the cell cycle in the G2/M phase and decreasing the synthesis of mucin-1 (MUC1) and expression of C-X-C motif chemokine 17 (CXCL17), which stimulates the tumor microenvironment [31]. The gene discussed is CXCL17; the disease is neoplasm.